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AbstrAct
Objective To examine health-related quality of life 
(HRQoL) and depression among participants in an 
international Sjögren’s syndrome (SS) registry, comparing 
those with and without SS.
Methods Cross-sectional study of participants in the 
Sjögren’s International Collaborative Clinical Alliance 
(SICCA) registry. The 2016 American College of 
Rheumatology/European League Against Rheumatism 
SS classification criteria were used to determine disease 
status. HRQoL was assessed using the Short Form 12, 
version 2 Health Survey to derive scores for physical 
component summary (PCS) and mental component 
summary (MCS). Depression was assessed using the 
9-Item Patient Health Questionnaire. Multivariate linear 
and logistic regression analyses were performed to identify 
predictors of HRQoL and depression while controlling for 
potential confounders.
Results Among 2401 SICCA participants who had 
symptoms of dry eyes and dry mouth, 1051 had SS (44%) 
and 1350 did not (56%). After controlling for confounders, 
when compared with non-SS participants, those with SS 
had better PCS (p<0.001, β=2.43, 95% CI 1.57 to 3.29), 
MCS (p=0.002, β=1.37, 95% CI 0.50 to 2.23) and lower 
adjusted odds of depression (p<0.001, OR 0.67, 95% CI 
0.55 to 0.81). Other significant predictors of HRQoL and 
depression included employment, country of residence 
and use of medication with anticholinergic effect or for 
management of SS-related signs and symptoms.
Conclusion Our results suggest that among symptomatic 
patients, having a diagnosis of SS may be associated with 
better emotional and psychological well-being compared 
with patients without a diagnosis. Having a definitive 
diagnosis of SS may encourage patients to obtain a 
better understanding of their disease and have coping 
mechanisms in place to better manage their symptoms.
IntROduCtIOn
Sjögren’s syndrome (SS) is a chronic autoim-
mune disorder characterized by salivary and 
lacrimal gland dysfunction due to chronic 
inflammation. In addition to autoantibody 
production, a wide variety of other systemic 
manifestations, such as cutaneous vasculitis 
and musculoskeletal pain, may also develop.1 
SS is estimated to affect 0.06% individuals 
worldwide and has a strong female predomi-
nance with an estimated female to male ratio 
of 9:1.2 As a chronic disease, SS can become 
progressively disabling as increasing oral and 
ocular dryness may interfere with basic daily 
functions.3–8 Currently available therapeutic 
options for SS are palliative, and limited 
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Sjögren syndrome
Key messages
What is already known about this subject?
 ► Sjögren’s syndrome (SS) is associated with 
significant morbidity, so exploring health-related 
quality of life (HRQoL) and depression are important 
first steps in developing strategies to improve it.
What does this study add?
 ► This study explored the association between HRQoL 
and depression among individuals who fulfilled the 
2016 American College of Rheumatology/European 
League Against Rheumatism classification criteria 
for SS using the Short Form 12, version 2 and the 
9-Item Patient Health Questionnaire, respectively, 
among a large, well-characterized cohort of 
adults participating in the Sjögren’s International 
Collaborative Clinical Alliance (SICCA) registry.
 ► We found that symptomatic individuals with SS 
participating in the SICCA registry had higher 
perceived HRQoL and lower odds of depression 
compared with individuals in the registry without 
SS.
How might this impact on clinical practice?
 ► This suggests that in a population of symptomatic 
patients, those who have an actual diagnosis of SS 
fare better, with respect to HRQoL and depression, 
than those who do not. This finding underscores 
the importance of being able to provide patients 
with a disease classification status so that they 
may pursue appropriate treatment and other 
alternatives.
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research has been done to assess the effects of systemic 
medications on exocrine and extraglandular damage. 
Therefore, assessing health-related quality of life 
(HRQoL) has emerged as an important clinical outcome 
of patient-centered care in SS.
HRQoL is a multidimensional concept that describes 
aspects of quality of life, including self-perceived well-
being and functionality, relating specifically to a person’s 
health.9 Compared with healthy controls, individuals 
with SS report significantly poorer physical capacity,10 11 
reduced productivity12 and more cognitive deficiencies.13 
Patients with SS also carry significant symptom burden, 
highlighted by studies that demonstrate dryness-related 
discomfort to be associated with HRQoL impairment, 
depression and anxiety.14–18 While oral and ocular dryness 
are strong predictors of diminished HRQoL in SS, these 
symptoms may be exacerbated by factors unrelated to 
SS, such as medication use, anxiety and allergies, which 
complicate this relationship. Therefore, the impact of 
SS on HRQoL and depression independent of oral and 
ocular symptoms should be examined.
In this analysis, we took advantage of the well-charac-
terized Sjögren’s International Collaborative Clinical 
Alliance (SICCA) dataset, which is the first international 
data registry that is geographically and socioeconom-
ically diverse. It employs standardised questionnaires 
to collect data on a wide array of outcome measures, 
including HRQoL and depression. Therefore, the SICCA 
dataset provides unprecedented opportunity to evaluate 
HRQoL and depression among an international group 
of individuals with SS or with signs and symptoms sugges-
tive of SS. The primary objective of this analysis is to 
compare HRQoL and depression scores of patients with 
SS to those without SS while exploring other relevant 
covariates and potential confounders. Furthermore, by 
focusing on symptomatic individuals with and without SS 
in this study, the association between SS and HRQoL and 
depression, unrelated to the effects of oral and ocular 
symptoms, is further explored.
MetHOds
study design and population
We conducted a cross-sectional study among participants 
in the SICCA registry. Enrolment occurred between 2004 
and 2012 within nine academically based research sites 
located in seven countries (Argentina, China, Denmark, 
India, Japan, UK and the USA) and directed by investi-
gators at the University of California San Francisco in 
the USA, where both the data coordinating center and 
biorepository are located. Details regarding the SICCA 
study design and population, including recruitment 
and eligibility criteria, have been previously described.19 
Additional information can also be found at http:// sicca- 
online. ucsf. edu.
The present analysis involved all individuals enrolled 
in the SICCA registry for whom data relevant to the 
outcomes of interest were available. Individuals with 
another concurrent autoimmune connective tissue 
disease diagnosis such as rheumatoid arthritis, systemic 
lupus erythematosus or sarcoidosis were excluded from 
the current study due to those disease associations with 
HRQoL and depression. Participants who reported either 
dry mouth or dry eyes (and not both) were also excluded 
from the study in order to establish uniform symptomatic 
and asymptomatic groups for our stratified analyses.
Variables and measures
Demographics
Information on gender, age, highest level of education 
(high school, college), employment (employed, unem-
ployed), self-reported race/ethnicity (White, Hispanic, 
African American, Asian, Native American), country of 
residence (Argentina, China, Denmark, India, Japan, 
UK, USA), medication use with anticholinergic effects 
and systemic medication use for the management of 
SS-related symptoms (non-steroidal anti-inflammatory 
drugs (NSAIDS), cholinomimetic drugs, antimalarials 
and others (corticosteroids, alkylating agents, antime-
tabolites, tumour necrosis factor (TNF)-alpha inhibitors, 
disease-modifying antirheumatic drugs (DMARDS), anti-
CD-20 and other immune-modifying biological agents)) 
were collected as part of the various questionnaires 
administered at the time of study entry. All of the afore-
mentioned data were self-reported. In addition, trained 
SICCA team clinicians (including oral medicine special-
ists, ophthalmologists and rheumatologists) performed 
focused protocol-driven clinical evaluations, which 
assessed for oral, ocular and rheumatological features. 
All serological test results were obtained from the same 
Quest laboratory. SICCA questionnaires, data collection 
forms and protocols are available for review at http:// 
sicca- online. ucsf. edu.
HRQoL: SF-12v2 Health Survey
SICCA participants completed the Short Form 12, 
version 2 (SF-12v2) survey, which is a self-report health 
survey pertaining to the previous 4 weeks.20 21 It is a vali-
dated alternative to its longer predecessor, the 36-Item 
Short Form (SF-36) health survey, and was created for 
studies with large sample sizes. This general health survey 
comprises 12 items representing eight subdomains of 
functional health and well-being: physical functioning 
(two items), role limitations due to physical problems 
(two items), bodily pain (one item), general health (one 
item), vitality (one item), social functioning (one item), 
role limitations due to emotional problems (two items) 
and mental health (two items). From these eight health 
subdomains, two summary scores can be derived: the phys-
ical component summary (PCS) and mental composite 
summary (MCS). Subscale and summary scores range 
from 0 to 100, with higher scores indicating better health. 
Generally, PCS and MCS are standardized to a mean of 
50 and SD of 10 using a 2009 US general population 
normative sample provided by Quality Metric. For this 
analysis, we examined differences in PCS and MCS raw 
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Table 1 Demographic characteristics by SS classification among 2527 SICCA* participants
SS participants  
n (%),  (N=1117)
Non-SS participants  
n (%), (N=1410) p Value
Age, median years (Q1–Q3) 52.4 (43–62) 53.5 (45–63) 0.03
Women 1049 (94) 1258 (89) <0.001
Race/ethnicity <0.001
  African 33 (3) 35 (2)
  Asian/Pacific Islander 424 (38) 243 (17)
  White 508 (46) 903 (64)
  Hispanic 112 (10) 168 (12)
  American Indian 39 (3) 60 (4)
Country of residence <0.001
  Argentina 122 (11) 202 (14)
  China 170 (15) 52 (4)
  Denmark 145 (13) 300 (21)
  India 48 (4) 30 (2)
  Japan 152 (14) 113 (8)
  UK 91 (8) 120 (9)
  USA 389 (35) 593 (42)
College education 630 (58) 899 (64) 0.001
Employed 563 (50) 638 (45) 0.009
Anticholinergic medication† 253 (23) 549 (39) <0.001
Medications‡ <0.001
  NSAIDS 105 (9) 231 (16)
  Cholinomimetics 75 (7) 60 (4)
  Antimalarials 130 (12) 118 (8)
  Other
  immunosuppressants§
191 (17) 162 (11)
  None 616 (55) 839 (60)
*Participants from the Sjögren’s International Collaborative Clinical Alliance registry.
†Participants who reported that they were taking a medication with anticholinergic effect at the time of study entry, such as antianxiety, 
antihypertensive, antidepressant, antihistamine/antiemetic, antipsychotic, antiparkinson, antiacne, decongestant, bronchodilator and muscle 
relaxant drugs.
‡Patient-reported systemic medications used for the management of SS-related symptoms and currently received at study entry.
§Include corticosteroids, alkylating agents, antimetabolites, tumour necrosis factor-alpha inhibitors, disease-modifying antirheumatic drugs, 
anti-CD-20 and other immune-modifying biological agents.
NSAIDS, non-steroidal anti-inflammatory drugs; SS, Sjögren’s syndrome.
scores between chosen characteristic subgroups (ie, age 
or SS classification) rather than the comparison of values 
to the US general population normative sample since this 
reference group would not serve as an adequate compar-
ison group for this international study.
Depression: 9-Item Patient Health Questionnaire (PHQ-9)
Depressive symptoms were assessed using the PHQ-9.22 
Health professionals use the PHQ-9 to screen for major 
depressive disorders and to monitor treatment, with 
clinical symptoms measured over the previous 2 weeks. 
A cumulative PHQ-9 score is obtained through summa-
tion of responses from the nine questions, each of which 
take on values in the range of 0–3. The resulting score 
ranges between 0 and 27. The PHQ-9 yields an index of 
depressive symptom severity with scores of 0–4 indicating 
no depression, 5–9 mild depression, 10–14 moderate 
depression, 15–19 moderately severe depression and 
20–27 severe depression.
SS classification criteria
The 2016 American College of Rheumatology (ACR)/
European League Against Rheumatism (EULAR) SS 
classification criteria23 24 used in this study are based 
on the weighted sum of five items: anti-Sjögren-specific 
antibody A (SSA)SSA/Ro antibody positivity25 and focal 
lymphocytic sialadenitis with a ≥1 focus/4 mm2 in a labial 
salivary gland biopsy,26 each scoring 3; an abnormal 
ocular staining score of ≥5,27 a Schirmer’s test result 
of ≤5 mm/5 min and an unstimulated salivary flow rate 
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Table 2 Sjögren’s syndrome (SS)-related characteristics stratified by SS classification and symptoms among 2527 SICCA* 
participants
Symptomatic participants (total=2401) Asymptomatic participants (total=126)
SS
(N=1051)
Non-SS
(N=1350) p Value†
SS
(N=66)
Non-SS
(N=60) p Value†
Symptoms, median years (Q1–Q3)
  Reported duration of dry 
mouth symptoms
4.0 (1.7–9.7) 2.9 (1.0–7.3) 0.002 NA NA NA
  Reported duration of dry eye 
symptoms
4.3 (1.8–9.8) 3.9 (1.4–9.1) 0.22 NA NA NA
SS-related findings, n (%)
  Labial salivary gland with FLS 
and FS ≥1 foci/4 mm
852 (82) 49 (4) <0.001 44 (67) 3 (5) <0.001
  Anti-SSA/Ro-positive 799 (76) 44 (3) <0.001 60 (91) 8 (13) <0.001
  OSS ≥5 in at least one eye 838 (80) 468 (35) <0.001 49 (74) 16 (27) <0.001
  Schirmer’s test ≤5 mm/5 min 
in at least one eye
614 (58) 389 (29) <0.001 20 (30) 10 (17) 0.08
  UWS flow rate ≤0.1 mL/min 748 (71) 582 (43) <0.001 17 (26) 6 (10) 0.02
*Participants from the Sjögren’s International Collaborative Clinical Alliance registry.
†Kruskal-Wallis test and χ2 test used to determine the relationship between SS and non-SS.
FLS, focal lymphocytic sialadenitis; FS, focus score; OSS, ocular staining score; NA, not applicable; UWS, unstimulated whole saliva.
of ≤0.1 mL/min, each scoring 1. Individuals with signs 
and/or symptoms suggestive of SS who have a total score 
of ≥4 for the above items meet the criteria for primary SS.
statistical analysis
We summarized baseline characteristics of our study 
sample using frequencies and percentages for categorical 
variables and median/quartiles for continuous variables. 
HRQoL scores for each of the eight SF-12v2 subdomains 
and the two component summary scores (PCS and MCS) 
were summarized using the mean and SD. We used the 
χ2 test to evaluate associations between categorical vari-
ables and the Kruskal-Wallis test to assess differences in 
distribution of continuous outcome variables between 
groups defined by categorical predictors. Interaction 
was detected when HRQoL outcome variables were strat-
ified by the presence of symptoms (ie, oral and ocular 
dryness) and SS classification. To manage this interac-
tion, multivariate analyses presented are restricted to 
the symptomatic subgroup. We used linear regression 
to assess marginal associations between HRQoL compo-
nent scores, SS classification and other selected variables. 
Logistic regression was used to evaluate marginal associ-
ations between depression (defined as having a PHQ-9 
score of ≥10) and these variables. Multivariate linear and 
logistic regression models were also fitted to explore the 
effects of adjustment for potential confounding variables, 
including demographic and socioeconomic characteris-
tics. Candidate adjustment variables were limited to those 
that were marginally associated with these outcomes at 
the 10% significance level. Variables were retained in 
the final model if they were found to be associated with 
the outcome at a significance level of at most 5% or if 
their removal resulted in a ≥10% change in estimated 
coefficients for the remaining covariates. Age, gender 
and country of residence were adjusted for in all models, 
regardless of statistical significance level in the unadjusted 
analysis. Diagnostic analyses were conducted to assess 
linearity, normality of residuals, multicollinearity and 
presence of outliers. All analyses were conducted using 
Stata V.12.0.
Results
demographic and sample characteristics
This study included 2527 SICCA participants, which 
represents a subset of the SICCA cohort who do not 
have a coexisting autoimmune connective tissue 
disease diagnosis and who also report having both 
dry eyes and dry mouth (or neither). One thousand 
one hundred seventeen participantsmet the ACR/
EULAR classification criteria for SS, and 1410 did not 
(table 1). As shown in table 1, participants who met SS 
criteria and those who did not differed with respect 
to a number of sociodemographic characteristics. Of 
note, the proportion of Asian/Pacific Islander partic-
ipants was significantly higher among SS participants 
(38%) than among those who did not meet SS criteria 
(17%). Similarly, participants from the China site had 
a higher representation among the SS group (15%) 
than among the non-SS group (4%). Not surprisingly, 
a higher proportion of non-SS participants (39%) 
than those with SS (23%) were taking a medication 
with anticholinergic effect.
Quality of life and depression scores by ss status, stratified 
by oral and ocular symptoms
Two thousand four hundred one participants reported 
symptoms of dry eyes and dry mouth, including 1051 
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Table 3 Health-related quality of life scores for SF-12v2 dimensions and PHQ-9 depression status stratified by SS 
classification and symptoms among 2527 SICCA* participants
Symptomatic participants (total=2401) Asymptomatic participants (total=126)
SS
(N=1051)
Non-SS
(N=1350) p Value†
SS
(N=66)
Non-SS
(N=60) p Value†
SF-12v2, mean±SD
 Physical function 46.0±10.7 42.6±11.5 <0.001 52.2±8.4 52.6±7.2 0.76
 Physical role functioning 44.2±10.3 40.1±10.4 <0.001 51.3±9.5 50.4±8.2 0.54
 Bodily pain 44.5±11.3 39.9±11.6 <0.001 50.6±10.3 49.6±9.6 0.57
 General health 41.8±10.7 40.5±11.2 0.004 44.5±10.6 46.8±10.4 0.22
 Vitality 47.0±11.2 43.6±10.8 <0.001 53.2±11.7 53.2±11.9 0.97
 Social functioning 46.0±10.4 42.7±11.2 <0.001 49.9±10.3 49.8±8.8 0.95
 Emotional role functioning 44.6±11.3 42.0±11.8 <0.001 50.5±10.0 50.2±8.5 0.85
 Mental health 46.5±10.6 44.2±10.5 <0.001 52.7±9.0 50.3±10.6 0.16
 Physical component measure 
(PCS)
44.2±10.3 40.5±11.4 <0.001 49.6±8.8 50.2±7.6 0.66
 Mental component measure (MCS) 46.4±10.3 44.3±10.8 <0.001 51.7±9.2 50.3±10.6 0.43
PHQ-9, n (%) <0.001 0.20
 No depression 439 (42) 388 (29) 55 (83) 41 (68)
 Mild 289 (27) 396 (29) 7 (11) 11 (18)
 Moderate 159 (15) 276 (20) 2 (3) 6 (10)
 Moderately severe 76 (7) 163 (12) 0 (0) 1 (2)
 Severe 39 (4) 97 (7) 2 (3) 1 (2)
*Participants from the Sjögren’s International Collaborative Clinical Alliance registry.
†Kruskal-Wallis test and χ2 test used to determine the relationship between SS and non-SS participants.
MCS, mental component summary; PCS, physical component summary; PHQ-9, 9-Item Patient Health Questionnaire; SF-12v2, Short Form 
12, version 2; SS, Sjögren’s syndrome.
with SS (44%) and 1350 without SS (56%) (table 2). 
There were 126 asymptomatic individuals, of whom 66 
met SS criteria (52%) and 60 did not (48%). Sympto-
matic patients with SS had longer median duration of dry 
mouth symptoms compared with those without SS (4.0 
vs 2.9 years, p=0.002). While a similarly high proportion 
of symptomatic and asymptomatic SS participants had 
an ocular staining score (OSS) ≥5, half the percentage 
of asymptomatic SS participants (30%) had a positive 
Schirmer’s test compared with those with symptoms 
(58%).
Symptomatic participants with SS had higher mean 
SF-12v2 scores in all eight HRQoL subdomains, including 
summary scores PCS and MCS, compared with non-SS 
symptomatic participants (table 3). Similarly, symptom-
atic individuals with SS had fewer reported symptoms of 
depression (26%) compared with those without SS (39%) 
(p<0.001). These results indicate that SICCA participants 
with SS had better self-perceived HRQoL and less depres-
sion compared with those without SS. Among asymptom-
atic participants, there were no statistically significant 
differences in HRQoL or depression levels between those 
with and without SS. The difference in statistical signifi-
cance of HRQoL and depression levels uncovered in the 
symptomatic subgroup compared with the asymptomatic 
group, where none was found, suggested an interaction 
of symptoms on the HRQoL/depression and SS status 
association. Therefore, in the subsequent multivariate 
analysis, we restricted the analysis to symptomatic SS 
participants.
Quality of life and depression in symptomatic sICCA 
participants: multivariate analyses
Multivariate analyses included 2401 symptomatic partici-
pants. After controlling for confounders, SS participants 
had a significantly higher adjusted mean PCS (ie, better 
physical HRQoL) compared with non-SS participants 
(table 4). Individuals living in the UK and China had 
a significantly higher mean PCS compared with those 
living in the USA. All unadjusted and adjusted regres-
sion coefficients, confidence intervals and p values are 
reported in tables 4 and 5, thus not duplicated in the 
text. In contrast, participants living in India had a lower 
mean score compared with those in the USA. Compari-
sons between other recruitment sites and the USA were 
not statistically significantly different. Use of medica-
tions with anticholinergic effect, antimalarials and other 
immunosuppressants were associated with lower mean 
PCS compared with not taking any of these medications. 
Also, being employed in a full-time occupation was asso-
ciated with a higher mean PCS compared with not being 
employed.
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Table 4 Associations of subject characteristics with mean SF-12v2 physical component scale scores among 2401 SICCA* 
participants with symptoms of dry eyes and dry mouth
Unadjusted β (95% CI) Unadjusted p
Multivariable adjusted 
β† (95% CI)
Multivariable 
adjusted p†
Age −0.04 (−0.08 to 0.01) 0.01 0.04 (0.01 to 0.08) 0.01
Gender, female 0.76 (−0.83 to 2.34) 0.35 0.54 (−0.95 to 2.03) 0.47
Country of residence
  Argentina 1.04 (−0.36 to 2.44) 0.14 0.16 (−1.15 to 1.47) 0.81
  China 4.88 (3.20 to 6.56) <0.001 1.99 (0.26 to 3.73) 0.02
  Denmark −0.54 (−1.77 to 0.70) 0.40 −1.14 (−2.34 to 0.06) 0.06
  India −0.23 (−2.53 to 2.06) 0.84 −4.04 (−6.45 to 1.64) 0.001
  Japan 0.98 (−0.65 to 2.61) 0.24 −1.30 (−2.87 to 0.27) 0.11
  UK 5.55 (4.01 to 7.09) <0.001 2.73 (1.24 to 4.22) <0.001
  USA Reference Reference
Education, college 0.27 (−0.64 to 1.19) 0.59
Employed 5.66 (4.81 to 6.51) <0.001 5.29 (4.41 to 6.17) <0.001
Meeting SS criteria 3.68 (2.79 to 4.57) <0.001 2.43 (1.57 to 3.29) <0.001
Anticholinergic medication −6.46 (−7.36 to 5.56) <0.001 −4.61 (−5.55 to 3.67) <0.001
Medications‡
  None Reference
  NSAIDS −5.89 (−7.18 to 4.60) <0.001 −4.38 (−5.63 to 3.13) <0.001
  Cholinomimetics −0.64 (−2.55 to 1.27) 0.51 −1.42 (−3.29 to 0.44) 0.14
  Antimalarials −4.27 (−5.75 to 2.80) <0.001 −4.03 (−5.47 to 2.59) <0.001
  Other immunosuppressants§ −4.89 (−6.17 to 3.61) <0.001 −4.33 (−5.58 to 3.07) <0.001
*Participants from the Sjögren’s International Collaborative Clinical Alliance registry.
†All factors with a p value ≤0.10 on univariate analysis entered into multivariate model; p value ≤0.05 to remain in final multivariate model.
 ‡Systemic medications used for the management of SS-related symptoms and currently received at study entry.
§Including corticosteroids, alkylating agents, antimetabolites, tumour necrosis factor-alpha inhibitors, disease-modifying antirheumatic 
drugs, anti-CD-20 and other immune modifying biological agents.
β, beta coefficient; NSAIDS, non-steroidal anti-inflammatory drugs; SF-12v2, Short Form 12, version 2; SS, Sjögren’s syndrome.
After controlling for other confounders, SS participants 
had a significantly higher adjusted mean MCS, reflecting 
better mental HRQoL, compared with non-SS partici-
pants (table 5). We found that those living in China and 
Denmark had a higher mean MCS compared with partic-
ipants living in the USA, whereas those living in the UK, 
Argentina and Japan had lower mean scores. Also, partic-
ipants who were taking medications with anticholinergic 
effect had a lower mean MCS compared with those who 
were not using any anticholinergic medication. No signif-
icant associations were found between MCS and educa-
tion, employment or use of other medications commonly 
used in the management of SS-related symptoms.
Similarly, SS participants also had significantly lower 
adjusted odds of developing depression compared with 
those participants without SS (table 6). All unadjusted 
and adjusted ORs, CIs, and p values are reported in 
table 6, thus not duplicated in the text. Individuals living 
in China or Denmark also had lower odds of depression 
compared with those living in the USA whereas partic-
ipants living in Argentina and Japan had higher odds 
of depression. Also, participants using medications with 
anticholinergic effect, NSAIDS and cholinomimetics had 
higher odds of depression compared with individuals not 
taking any of these medications. Being employed in a 
full-time occupation was associated with a lower adjusted 
odds of depression compared with not being employed.
dIsCussIOn
Contrary to our initial hypotheses, we found that sympto-
matic SICCA participants with SS had better physical and 
mental HRQoL, and lower depression scores than those 
without SS. While studies on HRQoL and depression in 
SS are limited, most have demonstrated reduced quality 
of life and depression in SS populations. For instance, in 
a large SS cohort in the USA, Segal et al found reduced 
physical and mental function in every domain of the SF-36 
compared with their healthy control group.14 However, 
our results demonstrated an inverse relationship between 
HRQoL and SS classification when comparing symp-
tomatic SICCA participants with SS with those without 
SS. After controlling for country of residence and other 
covariates, we found that individuals with SS had better 
7Chou A, et al. RMD Open 2017;3:e000495. doi:10.1136/rmdopen-2017-000495
Sjögren syndrome
Table 5 Associations of subject characteristics with mean SF-12v2 mental component scale scores among 2401 SICCA* 
participants with symptoms of dry eyes and dry mouth
Unadjusted β (95% CI) Unadjusted p
Multivariable adjusted β†
(95% CI)
Multivariable 
adjusted p†
Age 0.10 (0.07 to 0.13) <0.001 0.11 (0.08 to 0.15) <0.001
Gender, female −1.16 (−2.69 to 0.36) 0.14 −1.17 (−2.68 to 0.34) 0.13
Country of residence
  Argentina −3.14 (−4.48 to 1.80) <0.001 −3.11 (−4.43 to 1.79) <0.001
  China 5.72 (4.10 to 7.34) <0.001 3.82 (2.10 to 5.53) <0.001
  Denmark 1.42 (0.23 to 2.60) 0.02 1.21 (0.03 to 2.38) 0.04
  India 1.12 (−1.08 to 3.33) 0.32 0.09 (−2.31 to 2.49) 0.94
  Japan −0.63 (−2.20 to 0.93) 0.43 −1.65 (−3.23 to 0.06) 0.04
  UK −1.83 (−3.31 to 0.35) 0.02 −3.21 (−4.70 to 1.73) <0.001
  USA Reference Reference
Education, college 0.27 (−0.64 to 1.19) 0.56
Employed 0.28 (−0.56 to 1.13) 0.51
Meeting SS criteria 2.17 (1.32 to 3.03) <0.001 1.37 (0.50 to 2.23) 0.002
Anticholinergic medication −3.73 (−4.62 to 2.84) <0.001 −3.48 (−4.42 to 2.54) <0.001
Medications‡
  None Reference
  NSAIDS −1.03 (−2.30 to 0.25) 0.11
  Cholinomimetic drugs −0.85 (−2.73 to 1.04) 0.38
  Antimalarials −1.44 (−2.90 to 0.02) 0.06
  Other 
immunosuppressants§
0.23 (−1.03 to 1.50) 0.72
*Participants from the Sjögren’s International Collaborative Clinical Alliance registry.
†All factors with a p value ≤0.10 on univariate analysis entered into multivariate model; p value ≤0.05 to remain in model.
‡Systemic medications used for the management of SS-related symptoms and currently received at study entry.
§Include corticosteroids, alkylating agents, antimetabolites, tumour necrosis factor-alpha inhibitors, disease-modifying antirheumatic drugs, 
anti-CD-20 and other immune-modifying biological agents.
β, beta coefficient; NSAIDS, non-steroidal anti-inflammatory drugs; SF-12v2, Short Form 12, version 2; SS, Sjögren’s syndrome.
HRQoL and less depression than those without SS. This 
counterintuitive finding is likely the result of the heter-
ogeneous makeup of the SICCA cohort, specifically our 
comparison (non-SS) group. Having symptoms of dry 
eyes and dry mouth in a non-SS setting can be associated 
with having other conditions such as anxiety, depression 
and/or other systemic diseases such as fibromyalgia.28–31 
In fact, the non-SS group had a higher reported prev-
alence of moderate to severe depression (39% vs 26%, 
p<0.001) and reported higher use of anticholinergic 
medication (39% vs 23%, p<0.001) than SS participants. 
Anticholinergic agents are a broad class of medications 
that include antidepressants, anxiolytics, antipsychotics, 
sleep aids and antihistamines/antiemetics, which them-
selves can produce sicca symptoms as well. Thus, when 
compared with this distinct subgroup of non-SS individ-
uals, it may not be surprising to find that individuals with 
SS have better HRQoL and reduced depression levels.
Our results may also suggest that having a disease diag-
nosis may positively influence HRQoL while having symp-
toms without a known diagnosis may negatively impact 
it. Because many SICCA participants were recruited from 
existing SS clinics or from rheumatology offices, many 
individuals who met the ACR/EULAR classification 
criteria in our study had previously received a clinical 
diagnosis of SS. However, there was a subset of individ-
uals who presented with symptoms suggestive of SS, such 
as dry eyes and dry mouth, with no known disease diag-
nosis and who did not meet the classification criteria of 
SS. Because many autoimmune rheumatic diseases have 
overlapping disease profiles, individuals may not be easily 
categorized into an established clinical entity like SS. 
According to a study by Jones et al, at least 40% of patients 
in general practice do not have a diagnostic label, leaving 
most patients psychologically and emotionally vulner-
able.32 Without a known diagnosis, symptoms are difficult 
to manage long term. Among our SS subgroup, 36% of 
individuals had their disease managed with medications 
for SS such as cholinomimetics, antimalarials, corticoste-
roids, DMARDS and other immunomodulating agents 
compared with 23% of the non-SS subgroup. With the 
emergence of new biological agents, patients with a diag-
nosis of SS may also seek alternative treatments for SS 
through clinical trials. Furthermore, having a diagnosis 
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Table 6 Associations of subject characteristics with depression (PHQ-9 score ≥moderate depression) among 2401 SICCA* 
participants with symptoms of dry eyes and dry mouth
Unadjusted OR (95% CI) Unadjusted p
Multivariable adjusted 
OR† (95% CI)
Multivariable 
adjusted p†
Age 0.99 (0.98 to 0.99) <0.001 0.98 (0.97 to 0.98) <0.001
Gender, female 0.79 (0.58 to 1.08) 0.14 0.85 (0.61 to 1.20) 0.37
Country of residence
  Argentina 1.49 (1.15 to 1.93) 0.003 1.64 (1.25 to 2.15) <0.001
  China 0.13 (0.08 to 0.23) <0.001 0.24 (0.14 to 0.43) <0.001
  Denmark 0.68 (0.53 to 0.86) 0.002 0.72 (0.55 to 0.95) 0.02
  India‡ NA NA
  Japan 1.07 (0.79 to 1.46) 0.64 1.47 (1.05 to 2.04) 0.02
  UK 0.70 (0.52 to 0.95) 0.02 1.00 (0.72 to 1.39) 0.99
  US Reference Reference
Education, college 1.06 (0.89 to 1.26) 0.52
Employed 0.79 (0.67 to 0.94) 0.007 0.63 (0.52 to 0.76) <0.001
Meeting SS criteria 0.54 (0.45 to 0.64) <0.001 0.67 (0.55 to 0.81) <0.001
Anticholinergic medication 2.70 (2.26 to 3.22) <0.001 2.05 (1.68 to 2.50) <0.001
Medications§
  None Reference
  NSAIDS 2.03 (1.59 to 2.59) <0.001 1.58 (1.21 to 2.05) 0.001
  Cholinomimetics 1.76 (1.23 to 2.53) 0.002 1.62 (1.09 to 2.41) 0.02
  Antimalarials 1.78 (1.34 to 2.35) <0.001 1.35 (0.99 to 1.83) 0.06
  Other 
immunosuppressants¶
1.16 (0.89 to 1.49) 0.27 1.08 (0.81 to 1.44) 0.59
*Participants from the Sjögren’s International Collaborative Clinical Alliance registry.
†All factors with a p value ≤0.10 on univariate analysis entered into multivariate model; p value ≤0.05 to remain in final model.
‡9-Item Personal Health Questionnaire (PHQ-9) was not administered to individuals recruited from India.
§Systemic medications used for the management of SS-related symptoms and currently received at study entry.
¶Include corticosteroids, alkylating agents, antimetabolites, tumour necrosis factor-alpha inhibitors, disease-modifying antirheumatic drugs, 
anti-CD-20 and other immune-modifying biological agents.
NA, not applicable; NSAIDS, non-steroidal anti-inflammatory drugs; SS, Sjögren’s syndrome.
of SS enables patients to seek emotional and psycho-
logical support from other patients with SS in support 
groups. Therefore, having a definitive diagnosis of SS 
may encourage patients to obtain a better understanding 
of their disease and have coping mechanisms in place 
to better manage their symptoms. Healthcare providers 
must carefully evaluate disease phenotypic features so 
that they may provide patients with a disease classifica-
tion status to allow patients to develop effective coping 
and disease management strategies.
Several demographic and socioeconomic factors were 
also associated with HRQoL and depression in our anal-
ysis. We found that older age was associated with higher 
mental HRQoL and lower odds of depression. It is well 
established in the literature that ageing is associated 
with a reduction in anxiety and depression over time. A 
meta-analysis by Jorm et al examined the occurrence of 
anxiety, depression and general distress across the adult 
life span and found that there was an initial rise across 
age groups, which was then followed by a significant drop 
in anxiety and depression.33 We also found that country 
of residence was associated with specific varying HRQoL 
and depression scores. This is likely explained by differ-
ences in psychological and cultural factors that may affect 
perceptions of HRQoL within each country. Our obser-
vation that recruitment from China was positively asso-
ciated with PCS and MCS and negatively associated with 
depression could be impacted by the fact that prevalence 
of SS was higher among participants from that country 
relative to other registry sites, although controlling for 
country of residence in our multivariate analysis should 
address this. Furthermore, we found that employment 
is associated with better health outcomes, such as better 
physical health and less depression in our study popu-
lation. Perhaps having job security promotes income 
stability thereby stimulating better physical and mental 
health.
A unique strength of this study was the use of the 
well-characterized SICCA registry, which is an interna-
tional database consisting of geographically and socio-
economically diverse individuals with SS or signs and/
or symptoms suggestive of SS. Because of the suggested 
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interaction of symptoms on the HRQoL/depression and 
SS status relationship, and because of the small number 
of asymptomatic non-SS individuals, we limited our multi-
variate analysis to symptomatic individuals. Although this 
may not have allowed us to thoroughly explore the asso-
ciation of symptom burden of SS with respect to HRQoL 
and depression, it allowed us to explore this relationship 
independent of the effect of oral and ocular symptoms. 
The main limitation of our study is the absence of a 
healthy control group. Even among the 60 asymptom-
atic non-SS individuals in the SICCA cohort, 13% were 
positive for anti-SSA/Ro antibody, and 27% had OSS ≥5, 
suggesting some disease activity in this small group. 
Furthermore, because of the cross-sectional nature of the 
study, it is unclear if depression and poor HRQoL are a 
consequence or a cause of ocular and oral symptoms in 
the non-SS subgroup.
In conclusion, our focus on symptomatic individuals 
for the multivariate analysis allowed us to demonstrate 
the relationship between SS with respect to HRQoL and 
depression independent of oral and ocular dryness. Our 
findings suggest that obtaining a proper diagnosis is 
important for patient management so that appropriate 
treatment may be rendered to improve patient’s overall 
HRQoL.
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